ETA as a novel Kv2.1 inhibitor ameliorates β-cell dysfunction and hyperglycaemia

Area of Science:

• Biochemistry
• Pharmacology
• Endocrinology

Background:

• Kv2.1 channels are crucial for pancreatic beta-cell function and are implicated in type 2 diabetes.
• Dysfunction of these channels contributes to beta-cell failure, a key aspect of type 2 diabetes.

Purpose of the Study:

• To investigate the potential of a novel Kv2.1 inhibitor, ETA, as a therapeutic agent for type 2 diabetes.
• To evaluate ETA's effects on glucose-stimulated insulin secretion, beta-cell apoptosis, and glucose homeostasis in preclinical models.

Main Methods:

• In vitro studies using INS-832/13 pancreatic beta-cells to assess insulin secretion and apoptosis.
• In vivo studies using high-fat diet/streptozocin-induced type 2 diabetic mice to evaluate glucose homeostasis.
• Mechanistic studies involving protein kinase B (Akt) and extracellular signal-regulated kinase 1/2 (ERK1/2) signaling pathways.

Main Results:

• ETA treatment promoted glucose-stimulated insulin secretion and protected INS-832/13 cells from apoptosis.
• In type 2 diabetic mice, ETA significantly reduced fasting blood glucose and glycated hemoglobin levels.
• ETA administration improved oral glucose tolerance and increased serum insulin levels in diabetic mice, while modulating Akt and ERK1/2 pathways.

Conclusions:

• The Kv2.1 channel is a critical regulator of pancreatic beta-cell function.
• ETA demonstrates significant therapeutic potential as a lead compound for type 2 diabetes treatment due to its ability to improve glucose metabolism and protect beta-cells.